Last reviewed · How we verify
PVRV
At a glance
| Generic name | PVRV |
|---|---|
| Also known as | VERORAB® |
| Sponsor | University of Peshawar |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally (PHASE4)
- Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen (PHASE3)
- Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year (PHASE3)
- Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children (PHASE3)
- Diagnostic Immunization With Rabies Vaccine in Patients With PID (PHASE4)
- Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV (NA)
- Immunogenicity and Safety of Verorab™ in Indian Population (PHASE4)
- Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PVRV CI brief — competitive landscape report
- PVRV updates RSS · CI watch RSS
- University of Peshawar portfolio CI